EVMN
Evommune, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
6.61
▼ 0.04 (0.60%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
6.65
Day high
6.65
Day low
6.08
Volume
1.01M
Market cap
$239.89M
P/E (TTM)
—
52W range
6.08 – 33.20
Trailing performance
Returnvs SPY
1W
-20.84%
-22.8%
1M
-46.13%
-47.3%
3M
-50.11%
-54.6%
6M
-73.34%
-91.5%
YTD
-61.39%
-75.6%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on EVMN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-25.63K
Net selling
Buy transactions
7
75.22K shares
Sell transactions
8
100.85K shares
Net transactions
+15
Buys less sells
Sell : buy shares
1.3 : 1
Mixed
Insider-held shares
1.14M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 8, 26 | CARVER KYLE Chief Financial Officer |
BUY | 1.00K | $13.26K | Direct |
| Jul 7, 26 | KIRSCH ARTHUR S Director |
BUY | 10.00K | $133.00K | Indirect |
| Jun 22, 26 | PENA LUIS C Chief Executive Officer |
SELL | 7.44K | $168.92K | Direct |
| Jun 22, 26 | DREW JANICE SUZANN Officer |
SELL | 20.00K | $452.60K | Direct |
| Jun 22, 26 | PATEL JEEGAR PRAVINKUMAR PH.D. Officer |
SELL | 1.49K | $33.48K | Direct |
| Jun 22, 26 | DREW JANICE SUZANN Officer |
CONVERSION | 20.00K | $63.06K | Direct |
| Jun 22, 26 | PATEL JEEGAR PRAVINKUMAR PH.D. Officer |
CONVERSION | 1.49K | $5.71K | Direct |
| Jun 2, 26 | COHEN DAVID E Director |
SELL | 6.06K | $123.09K | Direct |
| Jun 1, 26 | PENA LUIS C Chief Executive Officer |
SELL | 16.79K | $381.74K | Direct |
| Jun 1, 26 | PATEL JEEGAR PRAVINKUMAR PH.D. Officer |
SELL | 16.69K | $379.46K | Direct |
| Jun 1, 26 | PATEL JEEGAR PRAVINKUMAR PH.D. Officer |
CONVERSION | 13.51K | $51.89K | Direct |
| May 28, 26 | CARVER KYLE Chief Financial Officer |
SELL | 18.18K | $415.12K | Direct |
| May 28, 26 | MOSS GREGORY S. ESQ. Officer |
SELL | 14.22K | $324.71K | Direct |
| May 28, 26 | CARVER KYLE Chief Financial Officer |
CONVERSION | 15.00K | $44.85K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAUER EUGENE A |
Officer and Director | 272.30K | Conversion of Exercise of derivative security |
CARVER KYLE |
Chief Financial Officer | 60.34K | Purchase |
DREW JANICE SUZANN |
Officer | 67.79K | Sale |
HOPFNER ROBERT LORNE |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
LSP 7 COOPERATIVE UA |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
MOSS GREGORY S. ESQ. |
Officer | 64.01K | Sale |
PENA LUIS C |
Chief Executive Officer | 630.46K | Sale |
PIVOTAL BIOVENTURE PARTNERS FUND I, L.P. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
RA CAPITAL MANAGEMENT, L.P. |
Director | — | Stock Award(Grant) |
WEEGEN FELICE VERDUYN-VAN |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
Fundamentals
Market cap$239.89M
Enterprise value$47.73M
Revenue (TTM)$10.00M
Gross profit$10.00M
EBITDA$-100.36M
Net income$-94.67M
EPS (TTM)$-3.75
Free cash flow$-39.13M
Total cash$200.79M
Total debt$8.63M
Book value / share$7.65
Shares outstanding36.29M
Float19.88M
Short % of float11.73%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.87
PEG ratio—
Price / sales—
Price / book0.86
EV / revenue4.77
EV / EBITDA-0.48
Gross margin100.00%
Operating margin-1018.94%
Profit margin0.00%
Return on equity-52.11%
Return on assets-31.99%
Debt / equity3.11
Current ratio11.68
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $13.00M | — | — |
| Operating revenue | $13.00M | — | — |
| Research & development | $74.04M | — | — |
| Selling, general & admin | $20.03M | — | — |
| Total operating expense | $94.07M | — | — |
| Operating income | -$81.07M | — | — |
| Net interest income | $3.32M | — | — |
| Pre-tax income | -$68.87M | — | — |
| Net income | -$68.87M | — | — |
| Net income to common | -$68.87M | — | — |
| Basic EPS | -11.22 | -4.27 | -162.8% |
| Diluted EPS | -11.22 | -4.27 | -162.8% |
| EBIT | -$81.07M | — | — |
| EBITDA | -$79.68M | — | — |
| Basic shares | 6.14M | 16.00M | -61.6% |
| Diluted shares | 6.14M | 16.00M | -61.6% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $44.06M | — | — |
| Cash & short-term investments | $149.20M | — | — |
| Total current assets | $153.48M | — | — |
| Property, plant & equipment | $2.46M | — | — |
| Total assets | $224.95M | — | — |
| Total current liabilities | $17.91M | — | — |
| Total debt | $1.71M | $1.02M | +67.6% |
| Total liabilities | $19.38M | — | — |
| Retained earnings | -$221.09M | — | — |
| Shareholder equity | $205.57M | — | — |
| Working capital | $135.57M | — | — |
| Net tangible assets | $205.57M | — | — |
| Shares issued | 31.52M | — | — |
| Line item | 2025 | YoY |
|---|---|---|
| Net income | -$68.87M | |
| Depreciation & amortisation | $1.39M | |
| Stock-based compensation | $5.86M | |
| Change in working capital | -$4.12M | |
| Operating cash flow | -$76.44M | |
| Capital expenditure | -$235.00K | |
| Investing cash flow | -$115.31M | |
| Financing cash flow | $220.76M | |
| Free cash flow | -$76.68M | |
| End cash position | $45.48M |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $10.00M | — | — |
| Operating revenue | $0 | $0 | $0 | $10.00M | — | — |
| Research & development | $26.41M | $17.32M | $20.40M | $19.64M | — | +52.5% |
| Selling, general & admin | $8.48M | $6.63M | $9.31M | $3.69M | — | +27.9% |
| Total operating expense | $34.90M | $23.95M | $29.72M | $23.33M | — | +45.7% |
| Operating income | -$34.90M | -$23.95M | -$29.72M | -$13.33M | — | -45.7% |
| Net interest income | $2.65M | $2.28M | $1.44M | $862.00K | $403.00K | +16.1% |
| Pre-tax income | -$32.25M | -$21.67M | -$28.27M | -$12.47M | — | -48.8% |
| Net income | -$32.25M | -$21.67M | -$28.27M | -$12.47M | — | -48.8% |
| Net income to common | -$32.25M | -$21.67M | -$28.27M | -$12.47M | — | -48.8% |
| Basic EPS | -0.89 | -0.64 | -1.43 | -0.41 | -0.45 | -39.1% |
| Diluted EPS | -0.89 | -0.64 | -1.43 | -0.41 | -0.45 | -39.1% |
| EBIT | -$34.90M | -$23.95M | -$29.72M | -$13.33M | — | -45.7% |
| EBITDA | -$34.34M | -$23.61M | -$29.39M | -$13.02M | — | -45.5% |
| Basic shares | 36.14M | 33.67M | 19.78M | 30.08M | 30.08M | +7.3% |
| Diluted shares | 36.14M | 33.67M | 19.78M | 30.08M | 30.08M | +7.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $60.03M | $48.32M | $44.06M | $26.82M | +24.2% |
| Cash & short-term investments | $200.79M | $211.46M | $149.20M | $76.06M | -5.0% |
| Total current assets | $204.25M | $215.85M | $153.48M | $81.94M | -5.4% |
| Property, plant & equipment | $9.22M | $9.57M | $2.46M | $1.13M | -3.7% |
| Total assets | $301.95M | $322.45M | $224.95M | $84.54M | -6.4% |
| Total current liabilities | $17.49M | $10.60M | $17.91M | $10.42M | +64.9% |
| Total debt | $8.11M | $8.55M | $1.71M | $160.00K | -5.1% |
| Total liabilities | $24.36M | $17.90M | $19.38M | $267.68M | +36.1% |
| Retained earnings | -$275.01M | -$242.76M | -$221.09M | -$192.82M | -13.3% |
| Shareholder equity | $277.59M | $304.56M | $205.57M | -$183.14M | -8.9% |
| Working capital | $186.76M | $205.25M | $135.57M | $71.53M | -9.0% |
| Net tangible assets | $277.59M | $304.56M | $205.57M | -$183.14M | -8.9% |
| Shares issued | 36.28M | 36.02M | 31.52M | 30.08M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | YoY |
|---|---|---|---|---|---|
| Net income | -$32.25M | -$21.67M | -$28.27M | -$12.47M | -48.8% |
| Depreciation & amortisation | $552.00K | $349.00K | $326.00K | $311.00K | +58.2% |
| Stock-based compensation | $4.60M | $3.45M | $4.20M | $560.00K | +33.1% |
| Change in working capital | $7.54M | -$8.84M | $7.64M | $2.48M | +185.2% |
| Operating cash flow | -$20.32M | -$27.50M | -$16.70M | -$9.63M | +26.1% |
| Capital expenditure | -$183.00K | -$83.00K | -$104.00K | — | -120.5% |
| Investing cash flow | $31.29M | -$85.36M | -$122.90M | -$23.91M | +136.7% |
| Financing cash flow | $532.00K | $117.11M | $156.85M | -$274.00K | -99.5% |
| Free cash flow | -$20.50M | -$27.59M | -$16.80M | -$9.77M | +25.7% |
| End cash position | $61.24M | $49.73M | $45.48M | $28.23M | +23.1% |
Options analytics
Put / call volume
1.00
Call-heavy session
Put / call open interest
0.34
Positioning, not flow
Max pain
10.00
+51.3% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+50.0%
Puts bid over calls
Call volume
20
Contracts, this expiry
Put volume
20
Contracts, this expiry
Heaviest call OI
10.00
521 contracts
Heaviest put OI
12.50
186 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.67 | -0.89 | -32.8% |
| Mar 2026 | -0.86 | — | — |
| Dec 2025 | -0.84 | -1.43 | -69.8% |
| Sep 2025 | -11.36 | -8.07 | +28.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.84 | 10 | $0 | -100.0% |
| Next quarter | -0.91 | 10 | $0 | 0.0% |
| Current year | -3.50 | 11 | $0 | -100.0% |
| Next year | -3.54 | 11 | $250.00K | 0.0% |
Analyst targets & ownership
Mean target$24.13
High target$30.00
Low target$18.00
Implied upside264.98%
Analyst count8
ConsensusBUY
Strong buy / Buy4 / 5
Hold2
Sell / Strong sell0 / 0
Held by insiders3.15%
Held by institutions114.74%
Institutions holding150
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
7.85
-15.74% from price
SMA 20
8.91
-25.83% from price
SMA 50
11.48
-42.40% from price
SMA 100
14.80
-55.35% from price
SMA 200
18.85
-64.94% from price
EMA 12
8.01
-17.51% from price
EMA 26
9.43
-29.87% from price
EMA 50
11.20
-40.96% from price
RSI (14)
17.9
Oversold
MACD (12,26,9)
-1.41
Hist -0.15
ATR (14)
0.58
8.84% of price
Realised vol 30D
76.0%
Annualised
Bollinger upper
11.47
20, 2σ
Bollinger lower
6.35
20, 2σ
50 / 200 cross
Death
11.48 vs 18.85
Trend bias
Below 200
-64.94%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.96
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
76.0%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-79.1%
Peak to trough
Max drawdown 5Y
-79.1%
Peak to trough
ATR 14
0.58
8.84% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
2.88M
Prior 4.70M
Change vs prior
-38.8%
Shorts covering
% of float
11.73%
Elevated
% of shares out
7.93%
Against total outstanding
Days to cover
4.7
Liquid
Float
19.88M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Sep 9, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 9, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Aug 26, 26 | Needham | INITIATED | — | Buy |
| Aug 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 3, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Jun 30, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jun 30, 26 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jun 29, 26 | William Blair | DOWNGRADE | Outperform | Market Perform |
| May 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 11, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Apr 10, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-01
Corporate Changes & Voting Matters
8-K · 2026-09-23
Corporate Changes & Voting Matters
8-K · 2026-09-15
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-06-02
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-04-22
Proxy Statements
DEF 14A · 2026-04-21
Headlines
EADV26: Key late-stage readouts from the conference
Clinical Trials Arena · 2d ago
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Business Wire · 6d ago
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Business Wire · 14d ago
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
Insider Monkey · 21d ago
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
BioPharma Dive · 26d ago
Sector Update: Healthcare Stocks Decline in Afternoon Trading
MT Newswires · 28d ago
This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
Investor's Business Daily · 28d ago
Sector Update: Healthcare Stocks Mixed Premarket Wednesday
MT Newswires · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.